BSEM.US BioStem Technologies, Inc. Common Stock

Healthcare Biotechnology USA Stocks
1.05 USD
Close of Nov 14, 2026
0.9000 8.40
Market cap
USD 20.1M
P/E
1.2x
P/B
0.87x
ROE
-39.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.

Is BSEM.US undervalued?

Graham number

The Graham number of BioStem Technologies, Inc. Common Stock cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BioStem Technologies, Inc. Common Stock fundamental analysis

No fundamental analysis for BioStem Technologies, Inc. Common Stock yet.

BioStem Technologies, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BioStem Technologies, Inc. Common Stock

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a human connective tissue matrix compromised of amniotic tissue intended for wound covering; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective …

Full company profile